Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • 1 April 2022 to 31 March 2023
  • Awards: Pump-priming Awards

Our past studies have shown that stimulating p21 activated kinase-1 (PAK1) in heart cells ameliorates pathological cardiac hypertrophy and fibrosis in animal models. In this project, we will evaluate a therapeutic strategy by using a small molecular {AK1 activator a disease-modifying therapy for familial hypertrophic cardiomyopathy (HCM).  The disease stage and time-dependent effects of PAK1 activators in ameliorating cardiac hypertrophy and fibrosis in HCM hearts will be examined and characterised.  The data generated will support developing drug-like small molecules targeting PAK1 as the springboard for further drug development for unmet medical needs of HCM.


Lei-Wang PP project April 2022